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Abstract
Objectives: Drainage after pancreaticoduodenectomy (PD) remains controversial because the risk for
uncontrolled postoperative pancreatic fistula (POPF) must be balanced against the potential morbidity
associated with prolonged and possibly unnecessary drainage. This study investigated the utility of the
level of serum amylase on the night of surgery [postoperative day (PoD) 0 serum amylase] to predict
POPF.
Methods: A total of 185 patients who underwent PD were studied. Occurrences of POPF were graded
using the International Study Group on Pancreatic Fistula (ISGPF) classification. Receiver operating
characteristic (ROC) analysis identified a threshold value of PoD 0 serum amylase associated with
clinically significant POPF (ISGPF Grades B and C) in a test cohort (n = 45). The accuracy of this threshold
value was then tested in a validation cohort (n = 140).
Results: Overall, 43 (23.2%) patients developed clinically significant POPF. The threshold value of PoD 0
serum amylase for the identification of clinically significant POPF was ≥130 IU/l (P = 0.003). Serum
amylase of <130 IU/l had a negative predictive value of 88.8% for clinically significant POPF (P < 0.001).
Serum amylase of ≥130 IU/l on PoD 0 and a soft pancreatic parenchyma were independent risk factors
for clinically significant POPF.
Conclusions: Postoperative day 0 serum amylase of <130 IU/l allows for the early and accurate cat-
egorization of patients at least risk for clinically significant POPF and may identify patients suitable for
early drain removal.
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Introduction
In-hospital mortality following pancreaticoduodenectomy (PD)
has decreased significantly over the last four decades, from 25%,
to currently accepted rates of <5% in high-volume centres
worldwide.1–4 Unfortunately, despite careful patient selection and
advances in perioperative management, surgical morbidity
remains high (40–50%).5 Postoperative pancreatic fistula (POPF)
persists as the most challenging and life-threatening complication
despite the application of numerous technical preventative
strategies.6–9
The occurrence of POPF has significant cost implications asso-
ciated with a prolonged postoperative stay,multiple investigations,
interventions and admissions to critical care environments.10–12 Of
greatest significance is the fact that complications associated with
POPF frequently delay or prevent the delivery of adjuvant chemo-
therapy, potentially impacting longterm survival.13 Subsequently,
the timely and appropriate determination of factors14–19 predictive
of risk for POPF is vital if themorbidity associated with pancreatic
resection is to be minimized.
Risk for POPF continues to fuel the controversy surrounding
the placement and timing of removal of operatively placed
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pancreatic drains. Prospective randomized evidence suggesting
that drain placement confers no objective benefit and may even
increase morbidity20 has been tempered by the early closure of a
recent randomized trial (NCT01441492) examining the hypoth-
esis that pancreatic resection without routine intraoperative
drainage is associated with decreased postoperative morbidity.21
Certainly, for themajority of pancreatic surgeons, intraoperative
drain insertion remains a standard component of PD.Drains serve
firstly to identify and control reactionary haemorrhage or bile leak
in the initial 24 h and, secondly, as a theoretical mechanism to
maintain control in the event of POPF formation.However, the risk
for infection and the potential damage that may be induced by
mechanical pressure, erosion or suction remain concerning. It has
been demonstrated that prolonged drainage is associated with
increases in the rate of complications, length of hospital stay and
economic resource utilization.22 Consequently, for surgeons who
continue to place drains intraoperatively, early removal is desirable
in patients in whom this can be achieved safely. Evidence suggests
this strategy may avoid or attenuate complications, reducing
in-hospital stay and readmissions, and ultimately achieve the pro-
vision of cost-effective, high-quality health care.22
Drain fluid amylase content is integral to the diagnosis of POPF
andhasbeenemployedas an indicatorof risk forfistula as early as the
first postoperative day (PoD).17,23–26 However, drain fluid amylase
content is challenging to assess in the initial 24 h as a result of
haemolysis and lowdrain volume. In response to this, several studies
have investigated the relationship between the derangement of
routine and easily measured serum and urine biochemical markers,
and risk for POPF.27–29 Of note, a rise in serum amylase in the
immediate postoperative period has previously been associatedwith
an increased risk for POPF.22,30 Consequently, the current study
sought to assess the utility of serum amylase on the night of surgery
(PoD 0) to predict the occurrence of POPF in a cohort of 185
patients undergoing PD with routine intraoperative drain place-
ment, inaneffort to identifypatients suitable for earlydrain removal.
Materials and methods
Patients
All patients underwent surgical resection in the West of Scotland
Pancreatic Unit, Glasgow Royal Infirmary, Glasgow, UK, during a
5-year period (January 2008 to March 2013). Patients were sub-
mitted to either classical or pylorus-preserving PD (PPPD), per-
formed by three surgeons (CRC, CJM and EJD). This analysis
included patients undergoing resection for either benign ormalig-
nant disease. Resectability for malignant disease was classified in
accordance with previous trial inclusion criteria31 and has been
outlined in a prior publication.32 Localized lesions adjacent to the
superior mesenteric vein or portal vein required the resection of
the involved segment and vascular reconstruction.
Prospective data collection
Demographic, pathological and intraoperative data were recorded
in a prospectively maintained database populated from a combi-
nation of electronic patient records, preoperative imaging and
anaesthetic charts. Preoperative clinical data included age, gender,
body mass index (BMI), and the results of serum biochemical
investigations including serum bilirubin, urea and amylase. The
serum amylase measured throughout the study period was total
amylase. The POSSUM (physiological and operative severity score
for the enumeration of mortality and morbidity) index served as
an objective measure of comorbidity and preoperative physiol-
ogy.33 Preoperative computed tomography images were analysed
to calculate pancreatic duct diameter at the line of transection of
the pancreas anterior to the portal vein. Intraoperative data
included reconstruction technique, texture of the pancreatic
remnant and estimated blood loss. Blood loss data were compiled
from a combination of anaesthetic charts and perioperative
blood transfusion data. Specimens were dichotomized according
to whether their pathology was associated with hard pancrea-
tic parenchyma [pancreatic ductal adenocarcinoma (PDAC)
and chronic pancreatitis] or with soft or normal pancreatic
parenchyma (ampullary carcinoma, duodenal carcinoma, cho-
langiocarcinoma, neuroendocrine tumours and other lesions).
Outcome data included length of stay in a critical care environ-
ment [defined as either an intensive care unit (ICU) or a surgical
high-dependency unit (SHDU)] and length of postoperative hos-
pital stay. All postoperative complications were prospectively rec-
orded and graded in a detailed weekly consensus discussion by the
three operating pancreatic surgeons according to the International
Study Group on Pancreatic Fistula (ISGPF) and International
Study Group of Pancreatic Surgery (ISGPS) classifications23,34 and
the Clavien–Dindo classification.35 Complications of ISGPS
Grades B and C and Clavien–Dindo Grades III–V were considered
clinically significant. Mortality was recorded at 30-day and 90-day
time-points.
Operative procedure
All patients received i.v. prophylactic antibiotics and a somatosta-
tin analogue (octreotide 100 μg; Sun Pharmaceuticals UK Ltd,
Leeds, UK) subcutaneously at the induction of anaesthesia.
Octreotide was continued in the postoperative period for a total of
15 doses. The operative steps of PD and histological analysis were
performed as described previously.32
Pancreatic transection was performed with a scalpel, ultrasonic
scalpel or diathermydependingon the consultant’s preference.The
pancreatic remnant was anastomosed using a dual-layer, duct-to-
mucosa technique to either the jejunum [pancreaticojejunostomy
(PJ)] or the stomach [pancreaticogastrostomy (PG)] according to
the surgeon’s preference. Pancreatic stents were not routinely used.
Absorbable synthetic monofilament sutures (Biosyn™; Covidien,
Inc.,Mansfield,MA, USA) were used in both techniques, with 4–0
sutures for the PJ and 3–0 sutures for the PG. At the end of the
procedure, one or two non-suction drains (24-Fr, BLAKE®;
Ethicon, Inc., Somerville, NJ, USA) were routinely placed adjacent
to the pancreatic and biliary anastomoses.
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Perioperative management
In the immediate postoperative period all patients were admitted
to the SHDU. Perioperative care for all patients was directed by the
operating surgeon. Serum haematology and biochemistry labora-
tory measurements were performed daily from the preoperative
day until discharge. Specifically, a blood sample was obtained for
serum investigations (including amylase) on admission to the
SHDU at least 4 h after the construction of the pancreatic anas-
tomosis (PoD 0). Drain fluid volumes were recorded and drain
fluid was analysed for amylase content on PoDs 1 and 3 and
thereafter until removal. Octreotide (100 μg given subcutaneously
every 8 h) was administered for 5 days and proton pump inhibi-
tors continued indefinitely. The criteria for drain removal
remained constant over the study period. Drains were removed
when: (i) the volume of drainage amounted to <50 ml over 24 h;
(ii) the drain fluid amylase content was not diagnostic of POPF,
and (iii) no other clinical contraindication to drain removal (bile
or chyle leak) existed. During the study period, PoD 0 serum
amylase assessment did not influence drain removal. The
management of suspected fistulae included the provision of anti-
biotics, image-guided percutaneous drainage, and surgical explo-
ration with extensive peripancreatic drainage or completion
pancreatectomy.
Definitions of outcome measures
The upper normal limit for serum amylase at this institute was
100 IU/l. Pancreatitis was defined by a serum amylase level of
≥300 IU/l (three times the upper limit of normal). The normal
range for drain fluid amylase was less than three times the serum
amylase activity. A drain fluid amylase three times the serum
amylase activity on or after PoD 3 was diagnostic of POPF in
accordance with the current ISGPF definition.23 In short, an
ISGPF Grade A POPF was a transient fistula requiring no addi-
tional treatment and no prolongation of hospital stay; a Grade B
POPF required additional medication or treatment and led to a
prolonged hospital stay, and a Grade C POPF was a potentially
life-threatening event, often associated with post-pancreatectomy
haemorrhage (PPH) or sepsis requiring re-laparotomy. Grades B
and C POPF were defined as clinically significant.
Statistical analysis
Continuous data are presented as the median (range). Categorical
variables were compared using the chi-squared test. The Mann–
Whitney U-test was used to compare continuous variables. To
identify the optimum threshold value of PoD 0 serum amylase for
predicting POPF, receiver operating characteristic (ROC) analysis
was performed in a random sample of the cohort (n = 45).36 The
area under the curve (AUC) in ROC analysis is a measure of the
diagnostic accuracy of a test: an AUC value of >0.50 indicates the
ability of a test to significantly differentiate between positive and
negative outcomes with regard to the classification variable (in
this case, POPF of ISGPF Grades B and C). A diagnostic test with
an AUC of >0.75 is considered to have high diagnostic accuracy,
with at least 75% of patients with the condition of interest classi-
fied correctly.26 The utility of the threshold identified using
ROC analysis was subsequently confirmed in a validation group
(n = 140) that included the remainder of the study cohort.
Univariate binary logistic regression analysis with calculation of
odds ratios (ORs) and 95% confidence intervals (CIs) was used to
explore the association between perioperative clinicopathological
factors, including PoD 0 serum amylase and risk for POPF. Mul-
tivariate binary logistic regression analysis was performed on vari-
ables showing a significant association on univariate analysis (P <
0.05). Backward stepwise regression was used starting with a satu-
rated model and variables with a P-value of >0.1 were excluded at
each step until no more variables could be excluded. List-wise
deletion was performed in patients for whom data were missing.
Cox proportional hazards regression analysis was used to analyse
the relationship between perioperative risk factors and length of
hospital stay. A P-value of < 0.05 was considered to indicate sta-
tistical significance. All statistical analysis was performed using
IBM spss Version 19.0 (IBM Corp., Armonk, NY, USA).
Results
Clinicopathological characteristics of the entire
patient cohort
A total of 185 patients who underwent PD between January 2008
and March 2013 were included in the analysis. The demographic,
operative, pathological and treatment characteristics of the cohort
are summarized in Table 1. Eighteen (9.7%) patients required en
bloc vein resection. Themedian estimated blood loss was 1450 ml.
Postoperative complications
The overall complication rate was 61.1% (n = 113). The rate of
complications of Clavien–Dindo Grade IIIa and above was 34.6%
(n = 64). A total of 64 (34.6%) patients developed POPF; 21
(11.4%) patients developed Grade A, 27 (14.6%) developed Grade
B and 16 (8.6%) developed Grade C POPF. The rate of clinically
significant (ISGPF Grade B or C) POPF was 23.2%.
The rate of clinically significant PPH (ISGPS Grade B or C)
was 12.4% (n = 23). A total of 44 (23.8%) patients required
re-intervention in the form of percutaneous drainage of intra-
abdominal collections or mesenteric angiography and emboliza-
tion for PPH; of these, 22 (11.9%) patients required a
re-laparotomy to both control the source of sepsis and manage
the haemorrhage.
The rate of 90-day surgical mortality was 4.9% (n = 9). Four
(2.2%) deaths occurred as a consequence of PPH and associated
complications, three (1.6%) as a result of infected intra-
abdominal collections, one (0.5%) subsequent to multi-organ
failure following severe post-PD pancreatitis, and one (0.5%) fol-
lowing a postoperative myocardial infarction. Eight of the nine
patients who died developed Grade C POPF as defined by the
ISGPF.
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Table 1 Demographic, operative and pathological characteristics and postoperative outcomes in the study test and validation cohorts
Characteristic Total cohort
(n = 185)
n (%)
Test cohort
(n = 45, 24.3%)
n (%)
Validation cohort
(n = 140, 75.7%)
n (%)
P-valuea
Age, years ≤60 81 (43.8%) 16 (35.6%) 65 (46.4%)
>60 104 (56.2%) 29 (64.4%) 75 (53.6%) 0.202
Gender Female 59 (31.9%) 15 (33.3%) 44 (31.4%)
Male 126 (68.1%) 30 (66.7%) 96 (68.6%) 0.812
Body mass index, kg/m2 <25 78 (44.1%) 18 (40.0%) 60 (42.9%)
≥25 99 (55.9%) 23 (51.1%) 76 (54.3%) 0.981
Smoking No 101(62.3%) 28 (62.2%) 73 (52.1%)
Yes 61 (37.7%) 12 (26.7%) 49 (35.0%) 0.251
POSSUM score ≤14 6 (3.2%) 0 6 (4.3%)
>14 167 (90.3%) 43 (95.6%) 124 (88.6%) 0.153
Preoperative bilirubin, mmol/l ≤22 93 (50.3%) 22 (48.9%) 71 (50.7%)
>22 92 (49.7%) 23 (51.1%) 69 (49.3%) 0.832
Procedure Pylorus-preserving PD 42 (22.7%) 11 (24.4%) 32 (22.9%)
Classical PD 143 (77.3%) 34 (75.6%) 108 (77.1%) 0.827
Pancreatic anastomosis Pancreaticogastrostomy 33 (17.8%) 10 (22.2%) 23 (16.4%)
Pancreaticojejunostomy 152 (82.2%) 35 (77.8%) 116 (82.9%) 0.390
Pancreatic texture Hard 70 (37.8%) 18 (40.0%) 52 (37.1%)
Soft 71 (38.4%) 17 (37.8%) 54 (38.6%) 0.808
Pancreatic duct diameter, mm >3 133 (72.3%) 32 (71.1%) 101 (72.1%)
≤3 51 (27.6%) 12 (26.7%) 39 (27.9%) 0.940
Estimated blood loss, ml ≤1450 102 (55.1%) 24 (53.3%) 78 (55.7%)
>1450 83 (44.9%) 21 (46.7%) 62 (44.3%) 0.781
Postoperative day 1 urea, mmol/l ≤7.5 108 (58.4%) 23 (51.1%) 85 (60.7%)
>7.5 77 (41.6%) 22 (48.9%) 55 (39.3%) 0.257
Postoperative pancreatic fistulab No 121 (65.4%) 26 (57.8%) 95 (67.9%)
Grade A 21 (11.4%) 7 (15.6%) 14 (10.0%)
Grade B 27 (14.6%) 6 (13.3%) 21 (15.0%) 0.533
Grade C 16 (8.6%) 6 (13.3%) 10 (7.1%)
Post-pancreatectomy haemorrhageb No 160 (86.5%) 37 (82.2%) 123 (87.9%)
Grade A 4 (2.2%) 1 (2.2%) 3 (2.1%)
Grade B 7 (3.8%) 2 (4.4%) 5 (3.6%) 0.308
Grade C 14 (7.6%) 5 (11.1%) 9 (6.4%)
Cardiac complicationsc Grades 0–II 183 (98.9%) 44 (97.8%) 139 (99.3%)
Grades III–V 2 (1.1%) 1 (2.2%) 1 (0.7%) 0.396
Respiratory complicationsc Grades 0–II 178 (96.2%) 44 (97.8%) 134 (95.7%)
Grades III–V 7 (3.8%) 1 (2.2%) 6 (4.3%) 0.529
Intra-abdominal collectionc Grades 0–II 155 (83.8%) 38 (84.4%) 117 (983.6%)
Grades III–V 30 (16.2%) 7 (15.6%) 23 (16.4%) 0.890
Admissions to critical care 1 episode 148 (80.0%) 35 (77.8%) 113 (80.7%)
>1 episode 37 (20.0%) 10 (22.2%) 27 (19.3%) 0.669
Reoperation No 163 (88.1%) 38 (84.4%) 124 (88.6%)
Yes 22 (11.9%) 7 (15.6%) 16 (11.4%) 0.467
Pathology PDAC/chronic pancreatitis 79 (42.7%) 15 (33.3%) 64 (45.7%)
Other 106 (57.3%) 30 (66.7%) 76 (54.3%) 0.145
Length of stay, days, median (range)d Critical care 6 (2–60) 6.0 (2.0–52.0) 7.0 (3.0–60.0) 0.213
Overall 15 (6–127) 16.0 (6.0–68.0) 15.0 (6.0–127.0) 0.909
90-day mortality 9 (4.9%) 4 (8.9%) 5 (3.6%) 0.150
aChi-squared test.
bGrade refers to International Study Group of Pancreatic Surgery (ISGPS) post-pancreatectomy complications.
cGrade refers to Clavien–Dindo classification of generic complications.
dMann–Whitney U-test.
Body mass index data available for 177 patients; smoking status available for 162 patients; POSSUM score available for 173 patients; pancreatic remnant texture data available for 140
patients; pancreatic duct diameter data available for 184 patients.
POSSUM, physiological and operative severity score for the enumeration of mortality and morbidity; PDAC, pancreatic ductal adenocarcinoma; Other, ampullary adenocarcinoma,
cholangiocarcinoma, duodenal carcinoma, neuroendocrine tumour.
HPB 613
HPB 2014, 16, 610–619 © 2013 International Hepato-Pancreato-Biliary Association
Predicting clinically significant POPF using
serum amylase
Table 1 illustrates the similarities between the test and validation
cohorts with respect to demographic, operative and pathological
characteristics and postoperative outcomes.
The distribution of PoD 0 serum amylase in patients who went
on to develop clinically significant POPF and those who did not is
shown in Fig. 1a. Analysis by ROC (Fig. 1b) performed on the test
cohort revealed a significant association between PoD 0 serum
amylase and clinically significant POPF (AUC = 0.793, 95% CI
0.66–0.92; P = 0.003). The optimal threshold of PoD 0 serum
amylase for predicting clinically relevant POPF was 127.0 IU/l,
with sensitivity of 91.7% and specificity of 72.7%. This value was
corrected to 130 IU/l for clinical use and validated in the subse-
quent 140 patients (chi-squared test). A PoD 0 serum amylase of
≥130 IU/l was strongly associated with the occurrence of clinically
significant POPF (P < 0.001; sensitivity 71.0%, specificity 65.1%),
with a negative predictive value of 88.8%.When ROC analysis was
performed on the validation cohort (n = 140), or the entire cohort
(n = 185), the threshold value of PoD 0 serum amylase was similar
to that found when using the test group, and remained statistically
significant with only minor variations in the AUC.
Risk factors for POPF
Univariate and multivariate binary logistic regression analyses of
the associations between clinicopathological characteristics,
intraoperative factors, PoD 0 serum amylase (as a dichotomized
variable) and clinically significant POPF (Grade B or C) in the
entire cohort (n = 185) are shown in Table 2.
In a subset analysis examining the influence of pancreatic
parenchyma on the level of PoD 0 serum amylase and clinically
significant POPF, patients with a hard pancreatic remnant (n = 70)
had a lower frequency of clinically significant POPF (4.3%) com-
pared with those with a soft gland (39.4%). Serum amylase on
PoD 0 was elevated (≥130 IU/l) in 21.4% of patients with a hard
pancreatic remnant compared with 64.8% of patients with a soft
pancreatic remnant. Of 71 patients with soft pancreatic paren-
chyma, 25 (35.2%) had a PoD 0 serum amylase of <130 IU/l. Only
three of these patients developed a clinically significant POPF.
Serum amylase of <130 IU/l on PoD 0 had a negative predictive
PoD 0 Serum
amylase clinically
significant POPF
N
N
Area
Under
Curve 
P-value
P-value
95% Cl
Threshold
serum amylase
value (IU/L)
Sensitivity
Sensitivity
Specificity
Specificity
Positive
predictive
value
Negative
predictive
value
140 <0.001 71.0 65.1 36.7 88.8
ROC Analysis
Chi-squared test
45 0.793 0.003 0.66–0.92 127.0 91.7 72.7
(a) (b)
Figure 1 Distribution of postoperative day (PoD) 0 serum amylase in patients who did and did not develop clinically significant postoperative
pancreatic fistula (POPF). Median PoD 0 serum amylase was 92 IU/l (range: 19–906 IU/l) in patients with no POPF or Grade A POPF, and
217 IU/l (range: 19–1833 IU/l) in patients with Grade B or C POPF (Mann–Whitney U-test, P < 0.001). (b) Receiver operating characteristic
(ROC) analysis in the test cohort revealed a significant association between PoD 0 serum amylase and clinically significant POPF [area under
the curve (AUC) 0.793, 95% confidence interval (CI) 0.66–0.92; P = 0.003]. The optimal threshold of PoD 0 serum amylase for predicting
clinically relevant POPF was 127.0 IU/l, with sensitivity of 91.7% and specificity of 72.7%. ISGPF, International Study Group on Pancreatic
Fistula
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Table 2 The relationship between clinicopathological characteristics and clinically significant postoperative pancreatic fistula (ISGPS Grades
B and C) in patients undergoing pancreaticoduodenectomy (n = 185): binary logistic regression analysis
Univariate analysis Multivariate analysis
Variable n OR 95% CI P-value OR 95% CI P-value
Age
≤60 years 81
>60 years 104 2.12 1.02–4.40 0.043 4.67 1.50–14.60 0.008
Gender
Female 59
Male 126 1.74 0.79–3.82 0.169
Body mass index
<25 kg/m2 78
≥25 kg/m2 99 2.96 1.34–6.52 0.007 3.09 1.02–9.35 0.045
Smoking
No 101
Yes 61 0.79 0.36–1.71 0.545
POSSUM score
<14 6
≥14 167 0.61 0.11–3.45 0.576
Preoperative bilirubin
≤22 mmol/l 93
>22 mmol/l 92 0.75 0.38–1.49 0.407
Pancreatic texture
Hard 70
Soft 71 14.5 4.16–50.80 <0.001 9.50 2.33–38.78 0.002
Pancreatic duct diameter
>3 mm 133
≤3 mm 51 2.48 1.20–5.11 0.014
Procedure
Pylorus-preserving PD 43
Classical PD 142 1.75 0.72–4.27 0.221
Pancreatic anastomosis
Pancreaticogastrostomy 33
Pancreaticojejunostomy 151 1.82 0.66–5.10 0.252
Estimated blood loss
≤1450 ml 102
>1450 ml 83 0.97 0.49–1.92 0.919
PoD 0 serum amylase
<130 IU/l 105
≥130 IU/l 80 6.67 3.03–14.68 <0.001 7.44 2.24–24.70 0.001
PoD 1 urea
<7.5 mmol/l 108
≥7.5 mmol/l 77 1.66 0.83–3.29 0.149
Pathology
PDAC/chronic pancreatitis 79
Other 106 3.12 1.43–6.81 0.004
OR, odds ratio; 95% CI, 95% confidence interval; POSSUM, physiological and operative severity score for the enumeration ofmortality and morbidity;
PD, pancreaticoduodenectomy; PDAC, pancreatic ductal adenocarcinoma; Other, ampullary adenocarcinoma, cholangiocarcinoma, duodenal car-
cinoma, neuroendocrine tumour; PoD, postoperative day.
Body mass index data available for 177 patients; smoking status available for 162 patients; POSSUM score available for 173 patients; pancreatic
remnant texture data available for 140 patients; pancreatic duct diameter data available for 184 patients.
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value of 88.0% for clinically significant POPF in patients with soft
pancreatic parenchyma (Table S1, online).
Serum amylase, complications and length of stay
The relationship between PoD 0 serum amylase of ≥130 IU/l and
clinically significant postoperative complications is demonstrated
in Table 3. The median cumulative critical care environment (ICU
or SHDU) length of stay was 6 days (range: 2–60 days) and the
median postoperative hospital stay was 15 days (range: 6–127
days). The relationships between clinicopathological factors,
operative factors and length of stay were considered for those 176
patients alive at discharge (Table S2, online).
Predictors of postoperative hyperamylasemia
Logistic regression was used to determine clinicopathological and
operative covariates significantly associated with postoperative
hyperamylasemia (PoD 0 serum amylase of ≥130 IU/l) (Table S3,
online). A BMI of ≥25 kg/m2, a soft pancreatic remnant, a pancre-
atic duct diameter of <3 mm and non-PDAC or chronic pancrea-
titis pathology were significant by univariate analysis. After
adjusting for these factors in a backward stepwise fashion, only a
soft pancreatic remnant (OR = 5.30, 95% CI 2.32–12.13; P <
0.001) and non-PDAC or chronic pancreatitis pathology (OR =
2.78, 95% CI 1.22–6.38; P = 0.015) were found to be indepen-
dently associated with raised PoD 0 serum amylase.
Discussion
For the majority of pancreatic surgeons, intraoperative drainage
of the pancreatic anastomosis is a standard component of PD,
despite the weight of published evidence against it.20,22,37–39 Prac-
tice at the study institution favours the routine intraoperative
placement of a drain and selective early removal. In its effort to
identify patients in whom early drain removal may be appropri-
ate, this study is the first to document serum amylase on the night
of surgery (PoD 0 serum amylase) as an objective marker of
patients with a low risk for POPF in whom early drain removal
and rapid postoperative progress may be predicted.
Evaluation of the study cohort shows that the rate of occurrence
of at least one complication was high at 61.1%. This undoubtedly
represents detailed, rigorous, prospective recording of postopera-
tive events (rather than poor surgical technique) and is similar to
the figure of 54% reported in 553 patients undergoing routine
drainage at Memorial Sloan–Kettering Cancer Center after sur-
geries that included distal pancreatectomies and PDs.39 The 23.2%
rate of clinically significant POPF in the current cohort is likewise
broadly similar to that reported in the literature.40 The reported
rate of clinically significant PPH is also high, but, as noted by
Welsch et al., who documented an overall rate of PPH of 29.1%,
the rigorous application of ISGPS criteria can potentially result in
false positive reports of adverse events.41
Previously published evidence suggests that independent risk
factors for POPF include: (i) a soft pancreatic remnant; (ii) a small
pancreatic duct (≤3 mm in diameter); (iii) non-PDAC or chronic
pancreatitis pathology, and (iv) increased intraoperative blood
loss.6,16,19,42–45 However, these risk factors are dependent on subjec-
tive assessment by the operating surgeon; in particular, gland
texture (reflecting both pancreas fat content and fibrosis) and
pancreatic duct diameter remain challenging to quantify in a
standardized fashion despite their prominence in models of POPF
risk prediction and the proposal of a variety of assessment
techniques.46
Factors related to an elevated PoD 0 serum amylase in this study
included a soft pancreatic remnant, a pancreatic duct diameter of
<3 mm, BMI of ≥25 kg/m2 and non-PDAC or chronic pancreatitis
pathology; of these, the soft texture of the pancreatic remnant was
the dominant determinant (Table S2). The present authors there-
fore suggest that PoD 0 serum amylase is an aggregate measure of
established risk factors for POPF47 and could be utilized in the
Table 3 The relationship between postoperative day 0 serum
amylase of ≥130 IU/l, non-fistulous complications and reoperation
rates (n = 185)
Variable Postoperative day 0 serum amylase
<130 IU/l
(n = 105, 56.8%)
n (%)
≥130 IU/l
(n = 80, 43.2%)
n (%)
P-valuea
Postoperative pancreatic fistula (ISGPF)
No 84 (80.0%) 37 (46.3%)
Grade A 11 (10.5%) 10 (12.5%)
Grade B 6 (5.7%) 21 (26.3%) <0.001
Grade C 4 (3.8%) 12 (15.0%)
Post-pancreatectomy haemorrhage (ISGPS)b
No 94 (89.5%) 66 (82.5%)
Grade A 2 (1.9%) 2 (2.5%)
Grade B 3 (2.9%) 4 (5.0%) 0.173
Grade C 6 (5.7%) 8 (10.0%)
Cardiac complicationsc
Grades 0–II 105 (100%) 72 (97.5%)
Grades III–V 0 2 (2.5%) 0.104
Respiratory complicationsc
Grades 0–II 101 (96.2%) 77 (96.2%)
Grades III–V 4 (3.8%) 3 (3.8%) 0.983
Intra-abdominal abscessc
Grades 0–II 96 (91.3%) 59 (74.2%)
Grades III–V 9 (8.7%) 21 (25.8%) 0.001
Admissions to critical care
1 episode 93 (88.6%) 55 (68.8%)
>1 episode 12 (11.4%) 25 (31.2%) 0.001
Reoperation
No 97 (92.4%) 65 (81.3%)
Yes 8 (7.6%) 15 (18.7%) 0.023
aChi-squared test.
bGrade refers to International Study Group of Pancreatic Surgery (ISGPS)
classification of post-pancreatectomy complications.
cGrade refers to Clavien–Dindo classification of generic complications.
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immediate postoperative period as an objective confirmation of
intraoperatively derived risk factors for POPF.
Notably, even in patients with a soft pancreatic parenchyma,
low PoD 0 serum amylase was associated with a very low risk for
the occurrence of clinically significant POPF (Table S1), which
suggests this simple assessment provides risk stratification data
beyond those of gland texture and pancreatic duct size.
A potential explanation for the utility of serum amylase is
that an elevated PoD 0 level represents a marker of surgical
trauma to a functioning pancreas, rather than a fistula in evolu-
tion. The inflammatory insult of the subsequent postoperative
localized necrotizing pancreatitis (despite a ‘sub-diagnostic’
hyperamylasemia) may exacerbate the ongoing systemic inflam-
matory response to major abdominal surgery,48 leading to a
cascade of systemic and local effects, including but not limited to
POPF.49,50
A risk score is only of clinical utility if it carries the potential to
alter clinical management. The high negative predictive value
(88.8%) of a low PoD 0 serum amylase, in conjunction with low-
risk intraoperative factors, might identify patients at low risk for:
(i) clinically significant POPF; (ii) clinically significant infected
intra-abdominal collections, and (iii) a prolonged length of hos-
pital stay. Such patients therefore might have their drains removed
on PoD 1, potentially limiting drain-associated morbidity. By
contrast, patients with a PoD 0 serum amylase level of ≥130 IU/l
might benefit from prolonged drainage. This study provides jus-
tification for drain removal on the first postoperative day on the
basis of a PoD 0 serum amylase level of <130 IU/l. This drain
management strategy will identify reactionary haemorrhage or
bile leak, avoid the morbidity associated with prolonged and
unnecessary drainage, and retain control in patients at high risk
for POPF.
Limitations
Despite the retrospective nature of this non-randomized analysis
in a relatively small cohort operated in a single institution, the test
and validation cohort strategy utilized in this study provides
strong evidence for the utility of PoD 0 serum amylase to predict
POPF. Although these data generated through the analysis of a
routine and robust serum biochemical test are impressive, this
preliminary investigation has not demonstrated that acting upon
a PoD 0 serum amylase threshold will impact on POPF rate.
Further validation is necessary and is currently ongoing. Ideally, a
prospective trial of drain removal in the context of serum amylase
on PoD 0 will be necessary to generate Level I evidence that can
ultimately guide drain management in patients undergoing PD.
Conclusions
The results of the current study suggest that an elevated PoD 0
level of serum amylase represents a robust and objective predictor
of POPF. This simple and routine measurement provides confir-
mation of subjective intraoperatively derived risk factors for
POPF. Postoperative day 0 serum amylase identifies patients at
low risk for POPF and a complicated postoperative course, who
would potentially be suitable for selective, early drain removal,
thereby avoiding the potential morbidity associated with
prolonged drainage.
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